Candida albicans Infections: a novel porcine wound model to evaluate treatment efficacy.
Antifungal
Biofilm model
Burns
Candida albicans
Infection
New model
Porcine
Porcine model
Wound
Yeast
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
04 02 2022
04 02 2022
Historique:
received:
09
06
2021
accepted:
24
01
2022
entrez:
5
2
2022
pubmed:
6
2
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Candida albicans is a common cause of opportunistic mycoses worldwide and a major contributor in wound infections. The purpose of this study was to establish a fungal wound model and analyze the effects of a common antifungal agent against the proliferation of three C. albicans strains. Second degree burns were created, and then inoculated with one of three different C. albicans ATCC strains: 10261 reference strain, 64550 fluconazole resistant and 26310 fluconazole sensitive. After fungal inoculation, every wound was covered with dressings for 4 h to allow fungal colonization on every wound bed. After 4 h, the dressings were removed, and each wound was treated either once or twice daily with a topical terbinafine hydrochloride or left untreated. On days 2, 4 and 7 post inoculation, three wounds from each treatment group were scrub cultured and quantified. On day 2, wounds infected with the sensitive strains 26310 and 10261 and treated twice showed a significant reduction when compared against those infected wounds receiving once daily treatment. On day 4, wounds which were infected with C. albicans fluconazole sensitive (ATCC 26310) showed a significant reduction in fungal cell counts with treatment applied twice daily. A significant reduction in the colony counts was exhibited in all three strains at the seventh day with active as compared to the non-treated wounds. Twice daily treatment resulted in a lower fungal count than once daily treatment. Neither treatment was able to entirely eradicate C. albicans during the duration of this study. Establishing a reliable fungal wound model will help in the translational goal of identifying new antifungal that could be used clinically by wound care providers.
Identifiants
pubmed: 35120444
doi: 10.1186/s12866-022-02460-x
pii: 10.1186/s12866-022-02460-x
pmc: PMC8815218
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Informations de copyright
© 2022. The Author(s).
Références
Mol Immunol. 2015 Jul;66(1):14-21
pubmed: 25466611
Clin Exp Dermatol. 1989 Mar;14(2):98-100
pubmed: 2689019
Infect Disord Drug Targets. 2015;15(1):42-52
pubmed: 25809621
Adv Wound Care (New Rochelle). 2015 Jul 1;4(7):382-388
pubmed: 26155380
Clin Exp Dermatol. 1989 Mar;14(2):101-3
pubmed: 2689011
Antimicrob Agents Chemother. 2007 Oct;51(10):3743-6
pubmed: 17664323
Comp Med. 2010 Apr;60(2):142-8
pubmed: 20412690
J Burn Care Rehabil. 1986 Nov-Dec;7(6):488-91
pubmed: 3429480
Anat Histol Embryol. 2019 May;48(3):207-217
pubmed: 30648762
J Antimicrob Chemother. 2015 Apr;70(4):1083-93
pubmed: 25558078
Ostomy Wound Manage. 2008 Oct;54(10):16-8, 20, 22-5
pubmed: 18927480
Surg Infect (Larchmt). 2002 Winter;3(4):367-74
pubmed: 12697083
J Med Microbiol. 2012 Dec;61(Pt 12):1704-1708
pubmed: 22918868
Wound Repair Regen. 2019 Jul;27(4):360-365
pubmed: 30920083
Am J Med. 1984 May 15;76(5A):158-65
pubmed: 6372465
Mykosen. 1987 Jun;30(6):281-7
pubmed: 3306370
Curr Top Med Mycol. 1992;4:158-88
pubmed: 1732066
Antimicrob Agents Chemother. 2010 Oct;54(10):4474-5
pubmed: 20660685
Mycopathologia. 2020 Apr;185(2):299-306
pubmed: 31939052
Curr Med Mycol. 2015 Dec;1(4):26-32
pubmed: 28681001
Sci Rep. 2019 Mar 6;9(1):3763
pubmed: 30842579
Virulence. 2015;6(4):316-26
pubmed: 25785541
ILAR J. 2015;56(1):127-38
pubmed: 25991704
Nat Rev Dis Primers. 2020 Feb 13;6(1):11
pubmed: 32054846
Wound Repair Regen. 2001 Mar-Apr;9(2):66-76
pubmed: 11350644
Arch Argent Pediatr. 2011 Oct;109(5):441-4
pubmed: 22042076
J Drug Target. 2021 Jan;29(1):78-87
pubmed: 32723117
Clin Infect Dis. 1997 Jun;24(6):1122-8
pubmed: 9195068
Eur J Med Chem. 2019 Mar 1;165:93-106
pubmed: 30660829
Gerodontology. 2017 Sep;34(3):291-298
pubmed: 28556195
Aust Endod J. 2013 Apr;39(1):31-4
pubmed: 23551511
Wound Repair Regen. 2017 Sep;25(5):744-757
pubmed: 28960634
N Engl J Med. 2019 Sep 19;381(12):1188
pubmed: 31532984
J Med Microbiol. 2020 May;69(5):721-727
pubmed: 32369006
BMC Complement Altern Med. 2019 Jan 7;19(1):6
pubmed: 30612544
J Mycol Med. 2017 Dec;27(4):501-505
pubmed: 28967539
Clin Infect Dis. 1998 Oct;27(4):781-8
pubmed: 9798034
Curr Probl Dermatol. 1978;7:39-52
pubmed: 752456
J Antimicrob Chemother. 2009 Sep;64(3):567-70
pubmed: 19584104
Science. 1984 Jun 15;224(4654):1239-41
pubmed: 6547247
Antimicrob Agents Chemother. 2000 Sep;44(9):2373-81
pubmed: 10952582
J Burn Care Rehabil. 1996 Nov-Dec;17(6 Pt 1):558-61
pubmed: 8951545
Fungal Genet Biol. 2019 Nov;132:103255
pubmed: 31330295
Curr Clin Microbiol Rep. 2015 Jun 1;2(2):84-95
pubmed: 26120512
Rev Esp Quimioter. 2014 Sep;27(3):141-58
pubmed: 25229370
Clin Infect Dis. 2008 Jan 1;46(1):120-8
pubmed: 18171227
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
J Burn Care Res. 2010 Mar-Apr;31(2):257-63
pubmed: 20182372
J Nat Sci Biol Med. 2017 Jan-Jun;8(1):119-124
pubmed: 28250687
J Med Microbiol. 2013 Feb;62(Pt 2):232-240
pubmed: 22034160
Wound Repair Regen. 2008 Jan-Feb;16(1):23-9
pubmed: 18211576
Antimicrob Agents Chemother. 1996 Nov;40(11):2622-5
pubmed: 8913476
J Clin Exp Dent. 2014 Dec 01;6(5):e576-82
pubmed: 25674329
Intensive Care Med. 2003 Dec;29(12):2162-2169
pubmed: 13680110
Dermatol Ther. 2004;17(6):517-22
pubmed: 15571501
Intensive Crit Care Nurs. 2018 Jun;46:4-5
pubmed: 29548615
Am J Infect Control. 1993 Aug;21(4):189-95
pubmed: 8239049
Antimicrob Agents Chemother. 2015 May;59(5):2875-81
pubmed: 25753643
Surg Infect (Larchmt). 2021 Feb;22(1):83-87
pubmed: 33035112
Ann Pharmacother. 2015 Sep;49(9):1068-74
pubmed: 26104051
Antimicrob Agents Chemother. 1997 May;41(5):1156-7
pubmed: 9145888
Clin Infect Dis. 2003 Aug 15;37(4):543-50
pubmed: 12905139
Can J Microbiol. 2011 Mar;57(3):204-10
pubmed: 21358761
Clin Infect Dis. 1992 Sep;15(3):414-21
pubmed: 1520786
J Invest Dermatol. 1978 Dec;71(6):382-4
pubmed: 722115
Br J Dermatol. 1992 Feb;126 Suppl 39:2-7
pubmed: 1543672
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7369-76
pubmed: 26574795
mBio. 2016 Sep 06;7(5):
pubmed: 27601572
J Invest Dermatol. 2018 Oct;138(10):2095-2105.e1
pubmed: 30244718
Int J Mol Sci. 2012;13(3):2535-50
pubmed: 22489109
Br J Haematol. 2004 Jul;126(2):165-75
pubmed: 15238137
J Infect Dis. 2012 Dec 1;206(11):1790-7
pubmed: 22984120
J Chemother. 2001 Nov;13 Spec No 1(1):12-6
pubmed: 11936355
Surg Infect (Larchmt). 2003 Winter;4(4):345-54
pubmed: 15012861
J Endourol. 2019 Aug;33(8):668-672
pubmed: 30924689
Antimicrob Agents Chemother. 1987 Sep;31(9):1365-8
pubmed: 3674847
PLoS One. 2020 Jun 19;15(6):e0234656
pubmed: 32559761
Clin Microbiol Rev. 1996 Oct;9(4):499-511
pubmed: 8894349
Infect Dis Clin North Am. 2021 Dec;35(4):1027-1053
pubmed: 34752219
PLoS One. 2011;6(11):e27317
pubmed: 22076151